SEK 0.87
Key Takeaways
Risk factor
Very high price volatility
Profitability factor
Very favourable analyst view
About
Kancera AB (Publ) develops drugs for inflammatory diseases and cancer in Sweden and internationally. The company is developing small molecule drug candidates KAND567, which is in phase IIa clinical trial for inflammatory heart disease following infarction, as well as KAND145, which is in phase I study in healthy subjects to document desired dose levels against...
Company Valuation
Based on key historical and expected multiples, the stock is slightly undervalued relative to its peers. Specifically, the stock is 'cheap' on P/E.
Target Price
The average target price of KAN.ST is 1.7 and suggests 95% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incre
